Finnish innovators look for cure to healthcare challenges

Aalto University and Bayer in February announced they have expanded their collaboration on artificial intelligence-based solutions for enhancing the safety and efficacy of clinical drug research by embarking on a three-year project with HUS Helsinki University Hospital. The methods and algorithms developed as part of the collaboration will be applied to the patient data of the university hospital. "Combining real-world data and clinical research data involves several challenges," told Jussi Leinonen, principal clinical data scientist at Bayer. "With AI, it can be done much faster, more efficiently and also more reliably." The project partners believe artificial intelligence is a means to address numerous challenges associated with drug development, including its resource-intensive nature.